CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 150 target
Drug / intervention
focal brachytherapy boost to SBRTradiation
Likely dose
Not stated in record
Key inclusion· 4
  • ✓Histological diagnosis of prostate cancer planned for curative-intent HDR brachytherapy boost
  • ✓ECOG performance status 0-1
  • ✓Charlson Comorbidity Index ≤4
  • ✓Imaging-visible disease encompassing <50% of prostate gland
Key exclusion· 0

None specified.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04100174
NCT04100174Phase 2RecruitingUpdate OverdueUpdated 15mo ago · Completion was 13mo ago
Enrollment Stalled
Long Recruiting
Update Overdue
CompareCT.gov

Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy

Centre hospitalier de l'Université de Montréal (CHUM)·interventional·Posted Sep 24, 2019·Updated Mar 13, 2025

In Brief

A Phase 2 clinical trial evaluating focal brachytherapy boost to SBRT for Prostate Cancer. Currently recruiting, targeting 150 participants across 2 sites.

Signals

Enrollment appears stalled

Detailed Summary

To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesCanada
Collaborators--

Timeline

Phase 2RecruitingOverdue
2020202120222023202420252026
First PostedSep 24, 2019
Enrollment StartJul 1, 2019
Primary CompletionMay 30, 2025
Study CompletionJun 30, 2025
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 6.8 years ago

Interventions

focal brachytherapy boost to SBRTradiation

As above